Hironori Yoshida1, Hiroki Nagai2, Yuichi Sakamori2, Hiroaki Ozasa1, Takashi Nishimura3, Keisuke Tomii4, Toyohiro Hirai1, Yukinori Matsuo5, Yusuke Iizuka5, Takashi Mizowaki5, Kenichi Yoshimura6, Young Hak Kim7. 1. Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 2. Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 3. Department of Respiratory Medicine, Kyoto Katsura Hospital, Kyoto, Japan. 4. Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan. 5. Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 6. Center for Integrated Medical Research, Hiroshima University Hospital, Hiroshima University, Hiroshima, Japan. 7. Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan ekim@kuhp.kyoto-u.ac.jp.
Abstract
BACKGROUND: Concurrent chemoradiotherapy (CCRT) is the gold standard for limited-stage small-cell lung cancer (LS-SCLC); however, most patients inevitably experience relapse. We hypothesized consolidation amrubicin following CCRT to be a potential treatment for LS-SCLC. PATIENTS AND METHODS: All enrolled patients were treated using induction CCRT consisting of four cycles of etoposide and cisplatin plus concurrent thoracic radiotherapy. Eligible patients then received three cycles of amrubicin as consolidation therapy (consolidation population). The primary endpoint was the 2-year progression-free survival rate in the consolidation population. RESULTS: Of the 36 intention-to-treat patients, 28 (78%) received amrubicin and 24 (67%) completed all planned treatments. The 2-year progression-free survival rate and overall response rate were 35.7% and 86%, respectively. The median progression-free and overall survival were 14.3 and 60.9 months, respectively. There were no treatment-related deaths in the intention-to-treat population. CONCLUSION: This study was terminated due to slow patient accrual; however, this treatment strategy was feasible and demonstrated promising efficacy. Copyright
BACKGROUND: Concurrent chemoradiotherapy (CCRT) is the gold standard for limited-stage small-cell lung cancer (LS-SCLC); however, most patients inevitably experience relapse. We hypothesized consolidation amrubicin following CCRT to be a potential treatment for LS-SCLC. PATIENTS AND METHODS: All enrolled patients were treated using induction CCRT consisting of four cycles of etoposide and cisplatin plus concurrent thoracic radiotherapy. Eligible patients then received three cycles of amrubicin as consolidation therapy (consolidation population). The primary endpoint was the 2-year progression-free survival rate in the consolidation population. RESULTS: Of the 36 intention-to-treat patients, 28 (78%) received amrubicin and 24 (67%) completed all planned treatments. The 2-year progression-free survival rate and overall response rate were 35.7% and 86%, respectively. The median progression-free and overall survival were 14.3 and 60.9 months, respectively. There were no treatment-related deaths in the intention-to-treat population. CONCLUSION: This study was terminated due to slow patient accrual; however, this treatment strategy was feasible and demonstrated promising efficacy. Copyright
Authors: J P Pignon; R Arriagada; D C Ihde; D H Johnson; M C Perry; R L Souhami; O Brodin; R A Joss; M S Kies; B Lebeau Journal: N Engl J Med Date: 1992-12-03 Impact factor: 91.245
Authors: A T Turrisi; K Kim; R Blum; W T Sause; R B Livingston; R Komaki; H Wagner; S Aisner; D H Johnson Journal: N Engl J Med Date: 1999-01-28 Impact factor: 91.245
Authors: Joachim von Pawel; Robert Jotte; David R Spigel; Mary E R O'Brien; Mark A Socinski; Jörg Mezger; Martin Steins; Léon Bosquée; Jeffrey Bubis; Kristiaan Nackaerts; José M Trigo; Philip Clingan; Wolfgang Schütte; Paul Lorigan; Martin Reck; Manuel Domine; Frances A Shepherd; Shaoyi Li; Markus F Renschler Journal: J Clin Oncol Date: 2014-11-10 Impact factor: 44.544
Authors: Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Corinne Faivre-Finn; Michael Snee; Linda Ashcroft; Wiebke Appel; Fabrice Barlesi; Adityanarayan Bhatnagar; Andrea Bezjak; Felipe Cardenal; Pierre Fournel; Susan Harden; Cecile Le Pechoux; Rhona McMenemin; Nazia Mohammed; Mary O'Brien; Jason Pantarotto; Veerle Surmont; Jan P Van Meerbeeck; Penella J Woll; Paul Lorigan; Fiona Blackhall Journal: Lancet Oncol Date: 2017-06-20 Impact factor: 41.316